Pfizer’s Torcetrapib Shown Ineffective At Slowing Coronary Plaque Build-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
Uncertainty remains as to whether failures are class related or specific to torcetrapib, lead investigator Nissen tells “The Pink Sheet” DAILY.
You may also be interested in...
Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.
Top Ten Unpartnered Drugs: It's Tough To Make The Grade In CVD/Metabolics
Early-stage talent parade will be held at Windhover's Therapeutic Area Partnerships conference next week.
Merck Freezes Cordaptive ACHIEVE Trial
Imaging endpoint stalls cholesterol study, per a monitoring panel’s advice.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: